GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Return-on-Tangible-Asset

Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Return-on-Tangible-Asset : -0.53% (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Beijing Bohui Innovation Biotechnology Group Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥-16.2 Mil. Beijing Bohui Innovation Biotechnology Group Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥3,054.0 Mil. Therefore, Beijing Bohui Innovation Biotechnology Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -0.53%.

The historical rank and industry rank for Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300318' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -13.81   Med: 0.36   Max: 4.11
Current: -0.5

During the past 13 years, Beijing Bohui Innovation Biotechnology Group Co's highest Return-on-Tangible-Asset was 4.11%. The lowest was -13.81%. And the median was 0.36%.

SZSE:300318's Return-on-Tangible-Asset is ranked better than
80.12% of 1499 companies
in the Biotechnology industry
Industry Median: -36.14 vs SZSE:300318: -0.50

Beijing Bohui Innovation Biotechnology Group Co Return-on-Tangible-Asset Historical Data

The historical data trend for Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Bohui Innovation Biotechnology Group Co Return-on-Tangible-Asset Chart

Beijing Bohui Innovation Biotechnology Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 -13.81 -2.98 -0.89 0.32

Beijing Bohui Innovation Biotechnology Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.81 1.09 -0.54 -1.97 -0.53

Competitive Comparison of Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset falls into.


;
;

Beijing Bohui Innovation Biotechnology Group Co Return-on-Tangible-Asset Calculation

Beijing Bohui Innovation Biotechnology Group Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=9.246/( (2795.613+2927.653)/ 2 )
=9.246/2861.633
=0.32 %

Beijing Bohui Innovation Biotechnology Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-16.216/( (2927.653+3180.336)/ 2 )
=-16.216/3053.9945
=-0.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Beijing Bohui Innovation Biotechnology Group Co  (SZSE:300318) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Beijing Bohui Innovation Biotechnology Group Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Bohui Innovation Biotechnology Group Co Business Description

Traded in Other Exchanges
N/A
Address
Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097
Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.
Executives
Niu Shu Hui Executives
Di Xiao Feng Director
Yang Qi Director
Lu Xin Qun Directors, executives
Zhang Lei Director
Wan Zhang Geng Executives
Song Rui Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines